Clinical Research Directory
Browse clinical research sites, groups, and studies.
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Sponsor: Novo Nordisk A/S
Summary
The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.
Official title: A Multi-centre, Open-label, Single-arm, Non-interventional Post-marketing Study to Investigate Safety and Clinical Parameters of Alhemo® Under Routine Clinical Practice in Japan
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
23
Start Date
2024-08-08
Completion Date
2030-04-30
Last Updated
2025-08-29
Healthy Volunteers
No
Conditions
Interventions
Concizumab
Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
Locations (7)
Novo Nordisk Investigational Site
Toshima City, Tokyo, Japan
Mutsu general hospital
Aomori, Japan
Kyushu university hospital_Pediatrics
Fukuoka, Japan
Sapporo Tokushukai Hospital_Pediatrics
Hokkaido, Japan
Kagoshima City Hospital
Kagoshima, Japan
St. Marianna University School of Medicine Hospital_Pediatrics
Kanagawa, Japan
Tokyo Medical University Hospital
Tokyo, Japan